鼠李糖乳杆菌干预肠道菌群及脂质代谢治疗代谢相关性脂肪性肝病的研究进展  

Research progress of Lactobacillus rhamnosus intervention on intestinal flora and lipid metabolism in the treatment of metabolic associated fatty liver disease

作　　者：李梦月 刘雨 李校天[2] LI Mengyue;LIU Yu;LI Xiaotian(Department of Clinical Medicine,Hebei University of Engineering,Handan 056000;Department of Gastroenterology,Affiliated Hospital of Hebei University of Engineering,China)

机构地区：[1]河北工程大学临床医学院,河北邯郸056000 [2]河北工程大学附属医院消化内科

出　　处：《胃肠病学和肝病学杂志》2022年第2期141-145,共5页Chinese Journal of Gastroenterology and Hepatology

基　　金：河北省财政厅老年病防治研究项目(2016723)。

摘　　要：代谢相关性脂肪性肝病(metabolic associated fatty liver disease, MAFLD)现已成为全世界最常见的慢性肝病,发病率在逐年增加,目前无临床特效药,其发病机制复杂,主要涉及肥胖、肠道菌群、胰岛素抵抗、环境、遗传等。近年来,益生菌在预防和治疗MAFLD中被广泛研究,鼠李糖乳杆菌(Lactobacillus rhamnosus, LGG)属乳杆菌属的经典益生菌菌株。大量研究证明,LGG可通过调节肠道菌群、改善肠黏膜屏障及降低胆固醇改善MAFLD。本文主要阐述LGG干预MAFLD的相关可能机制。Metabolic associated fatty liver disease(MAFLD) is now the most common chronic liver disease worldwide, with incidence increasing year by year, there is no clinical specific drug nowadays, its pathogenesis is complex, mainly involving obesity, intestinal flora, insulin resistance, environment, genetics, etc. In recent years, probiotics are widely studied in the prevention and treatment of MAFLD, Lactobacillus rhamnosus(LGG) is a classical probiotic strain of Lactobacillus. Numerous studies have demonstrated that LGG may improve MAFLD by modulating intestinal flora, improving the intestinal mucosal barrier and reducing cholesterol. This article mainly illustrated the relevant possible mechanisms of LGG intervention in MAFLD.

关 键 词：代谢相关性脂肪性肝病 鼠李糖乳杆菌 肠道菌群 脂质代谢 

分 类 号：R575[医药卫生—消化系统]